Homocysteine, endothelial dysfunction and oxidative stress in type 1 diabetes mellitus

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 5, 2003, Pages 334-340

  Wotherspoon, Fiona ^a   Laight, David W ^b   Shaw, Kenneth M ^a   Clummings, Michael H ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Cardiovascular disease; Endothelium; Homocysteine; Microalbuminuria; Oxidative stress; Type 1 diabetes

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CYANOCOBALAMIN; CYSTATHIONINE; CYSTEINE; FOLIC ACID; HOMOCYSTEINE; SERINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIUM INJURY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; OXIDATIVE STRESS; PROTEIN METABOLISM; PROTEIN METHYLATION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

EID: 0242319800     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030050401     Document Type: Review

References (56)

1. Welch G, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
2. Deckert T, Poulson J, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. Survival, causes of death and complications. Diabetologia 1978;14:363-77.
3. Stephenson J, Kenny S, Stevens L, Fuller J, Lee E. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med 1995;12:149-55.
4. Vaccaro O, Perna AF, Mancini FP et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000;10:297-304.
5. Chico A, Perez A, Cordoba A et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998;41:684-93.
6. Hultberg B, Agardh E, Andersson A et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991;51:277-82.
7. Hofmann MA, Kohl B, Zumbach MS et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8.
8. Wilcken DEL. Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease. J Cardiovasc Risk 1998;5:217-21.
9. Powers H, Moat S. Developments in the measurement of plasma total homocysteine. Opin Clin Nutr Metab Care 2000;3:391-7.
10. McCully. Vascular pathology of homocysteinaemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
11. Graham I, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
12. Boushey C, Beresford S, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
13. Kaye J, Stanton K, McCann V, Vasikaran S. Homocysteine, folate, MTHFR genotype and vascular morbidity in diabetic subjects. Clin Sci 2002; 102:631-7.
14. Targher G, Bertolini L, Zenari L et al. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care 2000;23:524-8.
15. Neugebauer S, Tarnow L, Stehouwer C et al. Total plasma homocysteine is associated with hypertension in type I diabetic patients. Diabetologia 2002;45:1315-24.
16. Chiarelli F, Pomilio M, Mohn A et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr 2000;137:386-92.
17. Wiltshire E, Thomas DW, Baghurst P, Couper J. Reduced total plasma homocyst(e)ine in children and adolescents with type 1 diabetes. J Pediatr 2001;138:888-93.
18. Cotellessa M, Minniti G, Cerone R, Prigione F, Calevo MG, Lorini R. Low total plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 2001;24:969-71.
19. Pavia C, Ferrer I, Valls C, Artuch R, Colome C, Vilaseca MA. Total homocysteine in patients with type 1 diabetes. Diabetes Care 2000;23(1):84-7.
20. Cronin CC, McPartlin JM, Barry DG, Ferriss JB, Scott JM, Weir DG. Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998;21:1843-7.
21. Robillon J, Canivet B, Candito M et al. Type 1 diabetes mellitus and homocyst(e)ine. Diabetes Metab 1994;20:494-6.
22. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-13.
23. Wald D, Law M, Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-06.
24. Shcherbak N, Shutsleaya Z, Sheridina A, Lairionora V, Schwartz E. MTHFR gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol Genet Metab 1999;68:375-8.
25. Brattstrom L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
26. Perros F, Singh R, Laudlern C, Frier B. Prevalence of pernicious anaemia in patients with type 1 diabetes and autoimmune thyroid disease. Diabet Med 2000;17:749-51.
27. Holmes G. Coeliac disease and type 1 diabetes - the case for screening. Diabet Med 2001;18:169-77.
28. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999;55:1028-35.
29. Jacques P, Kalmbach R, Bagley P et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002;132:283-8.
30. Miller J, Ribaya-Mercado J, Russell R et al. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55:1154-60.
31. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med 2001;39:666-74.
32. Hultberg B, Agardh CD, Agardh E, Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study. Scand J Clin Lab Invest 1997; 57:595-600.
33. Bostom A, Brosnan J, Hall B, Nadeau M, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59-62.
34. Agardh CD, Agardh E, Andersson A, Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1994;54:637-41.
35. Rossing P, Astrup A, Smidt U, Parving H. Monitoring kidney function in diabetic nephropathy. Diabetologia 1994;37:708-12.
36. Agardh E, Hultberg B, Agardh CD. Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 2000;60:169-74.
37. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinaemia as an adverse cardiovascular risk factor in endstage renal disease. Circulation 1998;97:138-41.
38. Stehouwer C, Lambert J, Donker A, Van Hinsbergh V. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34(1):55-68.
39. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.
40. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb 1999;19:2922-7.
41. Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinuric subjects. Eur J Clin Invest 1999;29:659-62.
42. Collaboration HLT. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-8.
43. Woo K, Chook P, Lolin Y, Sanderson J, Metreweli C, Celermajer D. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol 1999;34:2002-06.
44. Title L, Cummings P, Giddens K, Genest J, Nassar B. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758-65.
45. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci 1999;96:235-9.
46. Doshi S, McDowell IFW, Moat S et al. Folate improves endothelial function in coronary artery disease, an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001;21:1196-202.
47. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98(1):5-7.
48. Heinecke J, Rosen H, Suzuki L, Chait A. The role of sulphur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262: 10098-103.
49. Jones B, Rose F, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994;105:165-70.
50. Upchurch G, Welch G, Fabian A et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-17.
51. Moat S, Bonham J, Cragg R, Powers H. Elevated plasma homocysteine elicits an increase in antioxidant enzyme activity. Free Rad Res 2000; 32:171-9.
52. Rabini R, Staffolani R, Fumelli P, Mutus B, Curatola G, Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 1998;41:101-04.
53. Mutus B, Rabini RA, Staffolani R et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001;44:979-82.
54. Kanani F, Sinkey C, Browning R, Allaman M, Knapp H, Haynes W. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1991;199:1161-8.
55. Nappo F, De Rossa N, Marfella R et al. Impairment of endothelial function by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-18.
56. Bonham J, Moat S, Bones C, McDowell I, Lewis M, Powers H. Oral ascorbic acid ameliorates homocysteine-mediated endothelial dysfunction in classical homocysteinuria both acutely and chronically. J Inher Metab Dis 2000;23(suppl):65.